R

REGENXBIO

Develops AAV gene delivery therapies

Accounts Payable Coordinator

Accounts Payable/ReceivableUpdated on Nov 10
Full-timeRockville, MD, USAHybrid

About the Job

Requirements

  • A bachelor's degree is required; accounting is preferred.
  • At least 2 years of experience in progressive accounts payable or similar roles.
  • Extensive experience with and understanding of the accounts payable process.
  • Understanding of accrual-based accounting concepts.
  • Experience working with enterprise resource planning systems; Oracle Fusion is preferred.
  • Experience processing expense reports.
  • Experience performing monthly financial close procedures, including journal entries and balance sheet reconciliations.
  • Strong organizational, analytical, interpersonal, and communication skills.
  • Ability to work independently and collaboratively in a fast-paced, high-volume environment.
  • Ability to budget and manage time appropriately.
  • Advanced proficiency in Excel.

Responsibilities

  • Process accounts payable, including managing inbound invoices through the accounts payable email system, processing invoices, and ensuring accurate coding for purchase order and non-purchase order invoices.
  • Reconcile supplier statements.
  • Assist with the monthly close process.
  • Work cross-functionally with stakeholders in various departments to resolve discrepancies.
  • Manage supplier relationships and payment inquiries.
  • Ensure compliance with internal controls and company policies.
  • Develop expert knowledge of accounting systems and continuously assess processes for improvement.
  • Participate in external audits and provide support as necessary.
  • Perform special projects and other tasks as needed by the Accounting Department.

Desired Qualifications

  • Public company, biotech, or pharmaceutical experience is preferred.
  • Experience with Oracle Fusion is preferred.

About the Company

REGENXBIO

Develops AAV gene delivery therapies

REGENXBIO focuses on gene therapy using its NAV Technology Platform, an adeno-associated virus (AAV) gene delivery system with exclusive rights to more than 100 AAV vectors. The company generates revenue by licensing its platform, collecting royalties, and engaging in collaborations, while also developing its own one-time gene therapies for retinal, rare, and neurodegenerative diseases. Key products in later-stage trials include ABBV-RGX-314 for wet AMD and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy, and RGX-121 for Hunter syndrome, with a goal to advance five new therapies to pivotal-stage or commercial status by 2025 and FDA review for RGX-121 targeted in early 2026. REGENXBIO differentiates itself by owning a broad AAV vector library and offering end-to-end capabilities—from research to manufacturing—alongside a diversified revenue model that includes royalties, collaborations, and milestones.

Company size
201-500
Company stage
IPO
Headquarters
Rockville, MD
Founded
2009

Recently Posted Jobs

Explore more opportunities at REGENXBIO

See more jobs